DISEASE INDICATIONS: Urothelial Carcinoma, Breast Cancer, Lung Cancer

MANUFACTURER: Roche Registration Limited

USAGE: Intravenous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Pharmaceuticals and Medical Devices Agency (PMDA)

Therapeutic Goods Administration (TGA)

Medsafe (NZ)

Tecentriq (Atezolizumab) is an immunotherapy drug used to treat advanced non-small cell lung cancer and urothelial carcinoma (bladder cancer). By blocking protein PD-L1, it helps the immune system attack and destroy cancer cells.